Press-release for stocks related to pharma for ocup

Prices are updated after-hours

tags : Pharma symbols : Ocup

save search

Ocuphire Pharma Announces Financial Results for Fourth Quarter and Full Year 2023 and Provides Corporate Update
Published: 2024-03-08 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -30.25% | O: -1.26% H: 0.0% C: -15.32%
pharma year update financial results

Ocuphire Pharma to Present in the BIO CEO & Investor Conference
Published: 2024-02-23 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -33.6% | O: 0.8% H: 0.34% C: -0.79%
pharma ceo conference

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -37.36% | O: -0.75% H: 3.07% C: 0.0%
pharma nasdaq grants

Ocuphire Pharma Strengthens Leadership Team with Key Appointments
Published: 2024-02-14 (Crawled : 13:00) - globenewswire.com
DERM | $3.45 -3.63% -3.77% 100K

| -22.67% | O: 0.0% H: 3.78% C: -0.89%
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -35.41% | O: 0.0% H: 2.14% C: 1.17%
pharma key

Ocuphire Pharma Announces Presentation on APX3330 at the Annual Angiogenesis, Exudation, and Degeneration 2024 Conference
Published: 2024-02-05 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -37.36% | O: 0.75% H: 0.37% C: -5.62%
apx3330 pharma conference presentation

Ocuphire Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-01-24 (Crawled : 21:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -38.52% | O: 0.0% H: 0.74% C: -0.37%
pharma nasdaq grants

Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions
Published: 2024-01-04 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -46.1% | O: 0.65% H: 2.58% C: 0.0%
fda pharma solution treatment trial agreement

Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIIIInvestor Call with CEO, George Magrath, M.D., M.B.A., M.S. on December 5, 2023
Published: 2023-11-30 (Crawled : 15:00) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -39.42% | O: 3.28% H: 8.48% C: 7.77%
pharma presentation innovation

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-11-27 (Crawled : 22:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -40.5% | O: 0.14% H: 0.0% C: -3.36%
pharma nasdaq grant

Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer
Published: 2023-11-27 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -41.24% | O: 0.53% H: 3.48% C: -1.76%
pharma

Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update
Published: 2023-11-13 (Crawled : 13:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -41.34% | O: 2.47% H: 4.14% C: -0.69%
pharma update financial results

Ocuphire Pharma Announces Successful End-of-Phase 2 Meeting with FDA for Oral APX3330 in Diabetic Retinopathy
Published: 2023-11-02 (Crawled : 12:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -42.16% | O: 5.23% H: 2.65% C: -8.94%
apx3330 fda pharma meeting diabetic phase 2

Ocuphire Pharma Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2023-11-01 (Crawled : 21:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -42.16% | O: 5.23% H: 2.65% C: -8.94%
pharma nasdaq grant

Ocuphire Pharma Announces Appointment of George Magrath, M.D., M.B.A., M.S., as Chief Executive Officer and Director
Published: 2023-11-01 (Crawled : 12:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -41.75% | O: -0.35% H: 2.82% C: 1.06%
pharma

Ocuphire Pharma to Present at AAO 2023 and Eyecelerator Retina Showcase
Published: 2023-10-26 (Crawled : 12:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -40.07% | O: 0.0% H: 3.61% C: 0.54%
pharma retina

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in OctoberPresentations Will Feature Data From ZETA-1 Phase 2 Trial of APX3330 in Diabetic Retinopathy
Published: 2023-10-06 (Crawled : 13:00) - biospace.com/
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -51.88% | O: -0.29% H: 2.62% C: 2.62%
apx3330 pharma retina trial diabetic

Ocuphire Pharma to Present at Euretina and Retina Society Conferences in October
Published: 2023-10-06 (Crawled : 12:00) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -51.88% | O: -0.29% H: 2.62% C: 2.62%
pharma retina

Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution)
Published: 2023-09-27 (Crawled : 13:00) - biospace.com/
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| 15.74% | O: 0.0% H: 1.03% C: -1.34%
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -58.71% | O: 0.75% H: 3.46% C: -6.67%
fda pharma approval ryzumvl

Ocuphire Pharma and Viatris Announce FDA Approval of RYZUMVI™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents
Published: 2023-09-27 (Crawled : 12:00) - globenewswire.com
VTRS A | $11.25 1.17% 1.16% 4.7M

Health Technology

| 15.74% | O: 0.0% H: 1.03% C: -1.34%
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology

| -58.71% | O: 0.75% H: 3.46% C: -6.67%
fda pharma approval treatment eye ryzumvl

Ocuphire Pharma to Participate in Three Upcoming Investment Bank Conferences
Published: 2023-09-11 (Crawled : 13:30) - globenewswire.com
OCUP | $1.66 -0.6% -0.6% 230K

Health Technology